New Alzheimer vaccine to be tested in Europe

Apr 23, 2010

A new vaccine against Alzheimer's, developed by the Austrian biotechnology firm Affiris, will soon be tested in six European countries, the company announced Friday.

Some 420 patients will be recruited to take part in clinical trials in Austria, Croatia, Czech Republic, France, Germany and Slovakia, Affiris said in a statement.

The AD02 vaccine, developed with British drugmaker , was already tested for safety and tolerability over the past year.

The clinical trials will now test its efficacy, with results expected as early as 2012, the company said.

ADO2 is meant to prevent the building up of beta-amyloid plaques in the brain, which cause the degradation of and are believed to play a crucial role in causing Alzheimer's disease.

The vaccine works by causing the body to attack these plaques by producing more antibodies, Till Jelitto, a spokesman for Affiris, told AFP.

More specifically, these are meant to attack only the part of the beta-amyloid protein that causes the plaques, he added.

This would reduce the risk for patients, as the protein as a whole already exists in healthy individuals.

The current vaccine is therapeutic, meaning it is aimed at treating patients already affected by the disease. But if results are positive, the technology could also be used to manufacture a prophylactic, or preventative, vaccine, Jelitto said.

In 2001, tests for a first vaccine against Alzheimer's disease were conducted in the United States and Europe but had to be cut short after serious side effects emerged.

Another was tested in Sweden in 2005.

, also known as AD, is a neuro-degenerative disease that affects cognitive functions, further impacting patients' behaviour and social adaptation.

The disease, which still has no known cure, affects about six million people in Europe every year.

Affiris is also working on vaccines against Parkinson's and .

Explore further: DR Congo Ebola outbreak has killed 42 since August: govt

add to favorites email to friend print save as pdf

Related Stories

Potatoes may hold key to Alzheimer's treatment

Aug 15, 2008

A virus that commonly infects potatoes bears a striking resemblance to one of the key proteins implicated in Alzheimer's disease (AD), and researchers have used that to develop antibodies that may slow or prevent the onset ...

Paving the way toward a vaccine against Alzheimer's disease

Jun 21, 2007

Scientists have provided new details about how proteins used to destroy bacteria and viruses may help treat Alzheimer’s disease. Gunnar K. Gouras, associate professor of neurology and neuroscience at Weill Medical College ...

Recommended for you

Africa's uneven health care becomes easy prey for Ebola

6 hours ago

Threatened by the possible spread of an Ebola epidemic which respects no borders, Africa is divided between a handful of countries equipped to withstand an outbreak and many more which would be devastated, experts say.

Ebola case stokes concerns for Liberians in Texas

7 hours ago

The first case of Ebola diagnosed in the U.S. has been confirmed in a man who recently traveled from Liberia to Dallas, sending chills through the area's West African community whose leaders urged caution ...

Is Australia prepared for Ebola?

10 hours ago

Australia needs to be proactive about potential disease outbreaks like Ebola and establish a national centre for disease control.

User comments : 1

Adjust slider to filter visible comments by rank

Display comments: newest first

ubavontuba
1 / 5 (1) Apr 24, 2010
What happened to Alzheimer's being caused by herpes simplex virus type 1 (HSV1)? Might a vaccine against HSV1 be more effective?

See:

http://www.physor...732.html